On Monday 20 December, the European Commission granted a conditional market authorisation for Nuvaxovid (NVX-CoV2373), the Covid-19 vaccine developed by the US pharmaceutical company Novavax.
This market authorisation, approved by the EU27, was decided in accordance with the recommendations of the European Medicines Agency (EMA), which had been examining this protein-based vaccine for almost 11 months.
The agency confirmed that the data on Nuvaxovid, including from two phase 3 clinical...